var data={"title":"Oprelvekin (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oprelvekin (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6686?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oprelvekin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oprelvekin (United States: Not available): Patient drug information&quot;</a> and <a href=\"topic.htm?path=oprelvekin-united-states-not-available-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oprelvekin (United States: Not available): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709182\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Oprelvekin has caused allergic or hypersensitivity reactions, including anaphylaxis. Permanently discontinue administration of oprelvekin in any patient who develops an allergic or hypersensitivity reaction.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203860\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Neumega [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203877\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Biological Response Modulator;</li>\n      <li>\n        Human Growth Factor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203862\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Neumega has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thrombocytopenia:</b> SubQ: 50 mcg/kg once daily until postnadir platelet count &ge;50,000/mm<sup>3</sup>. Begin ~6 to 24 hours after the end of chemotherapy. In studies, doses were administered for 10 to 21 days (do not administer for more than 21 days). Discontinue at least 2 days prior to the next planned chemotherapy cycle.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203863\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9604650\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">For dosage adjustment purposes, renal function may be estimated using the Cockcroft-Gault formula.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: Reduce dose to 25 mcg/kg once daily.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20548138\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203844\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neumega: 5 mg (1 ea [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203828\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49660521\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Neumega has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203847\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: For subcutaneous administration in the abdomen, thigh, or hip; outer upper arm may also be used (if not self-injecting). Rotate injection sites each day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203845\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Thrombocytopenia:</b> Prevention of severe thrombocytopenia and to reduce the need for platelet transfusions following myelosuppressive chemotherapy for nonmyeloid malignancy in adults who are at high risk for thrombocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203884\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oprelvekin may be confused with aldesleukin, Proleukin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neumega may be confused with Neulasta, Neupogen</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203835\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (children: 84%; adults: 20%), edema (59%), cardiomegaly (children: 21%), vasodilatation (19%), atrial arrhythmia (12% to 15%), palpitations (14%), syncope (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (41%), dizziness (38%), insomnia (33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Fluid retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;77%), vomiting (&le;77%), diarrhea (43%), mucositis (43%), oral candidiasis (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Febrile neutropenia (48%), anemia (dilutional; onset: 3 to 5 days; duration: &le;1 week)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Severe weakness (14%), periosteal disease (children: 11%), arthralgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctival edema (children: &le;57%; adults: &le;19%), conjunctival erythema (children: &le;57%; adults: &le;19%), conjunctival injection (children: &le;57%; adults: &le;19%),  papilledema (children: 16%; adults: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (48%), rhinitis (42%), cough (29%), pharyngitis (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (36%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Respiratory: Pleural effusion (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Amblyopia, anaphylactoid reaction, anaphylaxis, blindness, blurred vision, capillary leak syndrome, cardiac failure, cerebrovascular accident, chest pain, decreased visual acuity, dehydration, dysarthria, exfoliative dermatitis, facial edema, hemophthalmos, hypersensitivity reaction, hypervolemia, hypoalbuminemia, hypocalcemia, hypokalemia, hypotension, increased clotting factors (von Willebrand factor), increased serum fibrinogen, injection site reaction (dermatitis, local discoloration, pain at injection site), loss of consciousness, mental status changes, optic neuropathy, paresthesia, pericardial effusion, peripheral edema, pneumonia, pulmonary edema, renal failure, shock, skin discoloration, urticaria, ventricular arrhythmia, visual field defect, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203850\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to oprelvekin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203832\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anemia (dilutional): Dilutional anemia may occur due to increased plasma volume, presenting as moderate decreases in hemoglobin concentration, hematocrit, and red blood cells without a decrease in red blood cell mass; effect generally appears within 3 to 5 days of initiation of therapy and resolves over ~1 week following oprelvekin discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular effects: Arrhythmias (usually brief in duration), pulmonary edema, and cardiac arrest have been reported; use in patients with a history of atrial arrhythmia only if the potential benefit exceeds possible risks. Stroke has been reported in patients who develop atrial fibrillation/flutter while receiving oprelvekin (patients with a history of stroke or transient ischemic attack may be at risk for atrial fibrillation/flutter). Ventricular arrhythmia has also been reported, occurring within 2 to 7 days of treatment initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fluid retention: May cause serious fluid retention (reversible within several days after discontinuation), which may result in peripheral edema, dyspnea, pulmonary edema, capillary leak syndrome, atrial arrhythmias, and exacerbation of preexisting pleural effusion. Serious fluid retention (sometimes fatal) has been reported. Use with caution in patients with clinically evident heart failure or who may be susceptible to developing heart failure, patients receiving aggressive hydration, patients with a history of heart failure who are well compensated and receiving appropriate medical therapy, and patients who may develop fluid retention as a result of associated medical conditions or whose medical condition may be exacerbated by fluid retention. Monitor fluid and electrolyte status; preexisting fluid collections, including pericardial effusions or ascites, should also be monitored (may require drainage).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: <b>[US Boxed Warning]: Allergic or hypersensitivity reactions, including anaphylaxis, have been reported. Permanently discontinue in any patient developing an allergic or hypersensitivity reaction.</b> Reaction may occur with the first or with subsequent doses. Allergic reactions included facial/tongue/larynx edema, dyspnea, wheezing, chest pain, hypotension (including shock), rash, urticaria, flushing, fever, loss of consciousness, mental status changes, and/or dysarthria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Papilledema: Papilledema has occurred, usually following repeated cycles. The incidence of papilledema occurred more frequently in children. Use with caution in patients with preexisting papilledema or with CNS tumors; may worsen or develop during treatment. Patients experiencing oprelvekin-related papilledema may be at risk for visual acuity changes and/or visual field defects, ranging from blurred vision to blindness.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment (oprelvekin is renally eliminated); dosage adjustment required in severe renal impairment. Monitor fluid balance. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Begin 6 to 24 hours following completion of chemotherapy; safety and efficacy of oprelvekin administered immediately before or during cytotoxic chemotherapy or initiated at the time of expected nadir has not been established. Not indicated following myeloablative chemotherapy; increased toxicities (hypotension, tachycardia, edema, and conjunctival bleeding) were reported and efficacy was not demonstrated. A higher incidence of adverse events (fluid retention/overload, facial/pulmonary edema, capillary leak syndrome) has also been reported when used following bone marrow transplantation. Efficacy has not been evaluated with chemotherapy regimens &gt;5 days' duration or with regimens associated with delayed myelosuppression (eg, nitrosoureas, mitomycin). Safety and efficacy have not been established with chronic administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299793\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203837\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9542&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203840\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3277319\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3277361\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if oprelvekin is excreted in breast milk. Due to the potential for serious adverse reactions in breast-feeding infants, the manufacturer recommends a decision be made to discontinue breast-feeding or the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203842\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor electrolytes and fluid balance during therapy (including persisting fluid collections [pericardial effusions or ascites]); obtain a complete blood cell count (CBC) at baseline and at regular intervals during therapy; monitor platelet counts during the time of expected nadir and until adequate recovery has occurred; renal function (at baseline) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203831\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Oprelvekin is a thrombopoietic growth factor that stimulates megakaryocytopoiesis and thrombopoiesis, resulting in proliferation of megakaryocyte progenitors and megakaryocyte maturation, thereby increasing platelet production.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203849\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 5 to 9 days; Maximum effect: 14 to 19 days  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: Up to 7 days after discontinuation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Adults: 112 to 152 mL/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: &gt;80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: 6.9 &plusmn; 1.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 3.2 &plusmn; 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (primarily; predominantly as metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: Adults: 2.2 to 2.7 mL/min/kg; clearance decreases with age and is about 1.2 to 1.6 times faster in children than in adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323558\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Neumega Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $528.92</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539907\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Jijufen (CN);</li>\n      <li>Neumega (KR);</li>\n      <li>Plaquemax (BR);</li>\n      <li>Yi Xing (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Neumega (oprelvekin) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; January 2011.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9542 Version 89.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709182\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F203860\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F203877\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F203862\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F203863\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9604650\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20548138\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F203844\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F203828\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49660521\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F203847\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F203845\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F203884\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F203835\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F203850\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F203832\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299793\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F203837\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F203840\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3277319\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3277361\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F203842\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F203831\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F203849\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323558\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539907\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9542|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oprelvekin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Oprelvekin (United States: Not available): Patient drug information</a></li><li><a href=\"topic.htm?path=oprelvekin-united-states-not-available-pediatric-drug-information\" class=\"drug drug_pediatric\">Oprelvekin (United States: Not available): Pediatric drug information</a></li></ul></div></div>","javascript":null}